Clinical trial NCT06022016: Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
Official title: Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: DDX41 Gene Mutation
Keywords: GermlIne DDX41 mutation
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Idiopathic Cytopenia
LeUkemia
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
First posted: 2023-09-01
Enrollment: 910
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This is a multicenter, interventional, historico-prospective cohort pilot study aimed at specifying the phenotype of subjects carrying a constitutional familial DDX41 mutation, with a view to eventually publishing oncogenetic recommendations for carriers of this mutation.

The main objective of the LUCID project is to assess the cumulative risk of hematological diseases (Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or cytopenia) as a function of age in DDX41 germline mutation carriers.

This study will be carried out in two stages:

Stage 1: Inclusion of index cases in an oncogenetic consultation (salivary test, completion of an health self-questionnaire and collection of contact details for the related cases).

Stage 2: Proposition of participation to family members, by correspondence, and determination of carrier or non-carrier status of the constitutional familial DDX41 mutation (based on a salivary test).

A maximum of 210 index case patients and 700 family member will be included in this study.


Eligibility criteria: Index cases:

Inclusion Criteria:

1. Women or man aged ≥ 18 years old.
2. Personal history(s) of hemopathy or patient with hemopathy at the time of inclusion: acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), idiopathic cytopenia.
3. Patient with a tumor mutation of DDX41 with an allelic frequency (AF) ≥ 30% (with total depth of nucleotide position \>300x: provide tumor molecular analysis report).

   Special case of inclusion of deceased index cases: the DDX41 tumor mutation of interest must be accompanied by another somatic DDX41 mutation (the most frequent being p.R525H).

   Or patient known to be a constitutional carrier of a DDX41 mutation confirmed after oncogenetic consultation (in this case, provide constitutional analysis report).
4. Patient (or beneficiary) agreeing to release results of oncogenetic report.
5. Patient (or beneficiary) agrees to communicate the contact details of his relatives and that they may be contacted by mail to participate in the LUCID study.
6. Patient affiliated to a Social Health Insurance in France.
7. Patient able to participate and willing to give informed consent prior performance of any study-related procedures.

Exclusion Criteria:

1. No history of hemopathy or no current hemopathy.
2. Patient (or beneficiary) unable to complete questionnaire for social or psychological reasons.
3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Related cases (Family member):

Inclusion Criteria:

1. Women or man aged ≥ 18 years old.
2. Related in the 1st, 2nd or 3rd degree (parents, children, grandchildren, brothers, sisters, grandparents, nephews, nieces, uncles, aunts, great-grandparents) to an index case included in the LUCID study.
3. Agreeing to carry out a scientific salivary test for the constitutional research of the DDX41 mutation.
4. Patient affiliated to a Social Health Insurance in France.
5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures.

Exclusion Criteria:

1. Related in the 4th or 5th degree to an index case included in the LUCID study.
2. Person already identified as an index case in the LUCID study.
3. Person unable to complete questionnaire for social or psychological reasons.
4. Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Primary outcomes:
measure: The time to onset of hemopathy defined as the time between the date of birth and the date of diagnosis of an hemopathy.
timeFrame: 74 months after the study start date
Secondary outcomes:
measure: Post-transplant relapse-free survival defined as the time between the date of transplantation and the date of all-cause relapse or death.
timeFrame: 74 months after the study start date
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Chu de Bordeaux
city: Limoges
country: France
facility: Chu de Limoges
city: Marseille
country: France
facility: Institut Paoli-Calmettes
city: Montpellier
country: France
facility: Chu de Montpellier
city: Toulouse
country: France
facility: IUCT-O
Study officials:
References: